News und Analysen
![Lantheus and Progenics Agree to Amended Transaction Terms](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lantheus and Progenics Agree to Amended Transaction Terms
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative
![NanoString Highlights Groundbreaking Spatial Genomics Research Using Expanding Portfolio of GeoMx High-Plex RNA Atlas Products at 2020 Advances in Genome Biology and Technology (AGBT) Conference](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
NanoString Highlights Groundbreaking Spatial Genomics Research Using Expanding Portfolio of GeoMx High-Plex RNA Atlas Products at 2020 Advances in Genome Biology and Technology (AGBT) Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced ten scientific studies utilizing the GeoMx™ Digital
![ICON Acquires MedPass International](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
ICON Acquires MedPass International
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has
![New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for
![Premier Inc. ProvideGx™ Program Partners with Pfizer Inc. to Provide Corvert® and Vincristine to Providers](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Premier Inc. ProvideGx™ Program Partners with Pfizer Inc. to Provide Corvert® and Vincristine to Providers
Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Pfizer Inc. to supply Corvert® (ibutilide fumarate injection) and Vincristine Sulfate Injection, USP, to healthcare
![Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom continuous glucose monitoring systems
![Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom continuous glucose monitoring systems
![Agilent Technologies Reports First Quarter Fiscal Year 2020 Financial Results](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Agilent Technologies Reports First Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.36 billion for the first quarter ended Jan. 31, 2020, up 5.7% year over year (and up 2.4% on a core(1) basis).
On a GAAP basis
![Quidel to Present at Upcoming Conferences](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel to Present at Upcoming Conferences
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the
![Lantheus Holdings to Present at the 9th Annual SVB Leerink Global Healthcare Conference](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Lantheus Holdings to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of
![Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent
Medicare Accountable Care Organizations (ACOs) participating in the Premier Inc. (NASDAQ: PINC) Population Health Management Collaborative (PHMC) have outperformed their peers by 21 percent in
![Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8:00 a.m. Eastern Time](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Tuesday, February 25, 2020, to discuss its financial and operating
![Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will
![European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary
![European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary
![NanoString to Present at the 40th Annual Cowen Healthcare Conference](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
NanoString to Present at the 40th Annual Cowen Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the company’s management is scheduled to present at the 40th
![Canopy Growth: Das war der Befreiungsschlag!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Canopy Growth: Das war der Befreiungsschlag!
Wie ein zu Barrons gehörendes bedeutendes Online-Finanzportal berichtet, würden die Anleger billiges Marihuana bevorzugen. Canopy Growth (WKN: A140QA) sei dabei derjenige Branchenplayer, der im
![Lysogene Reports its Cash Position as of 31 December 2019](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Lysogene Reports its Cash Position as of 31 December 2019
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
![Canopy Growth: Was Aurora kann...](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Canopy Growth: Was Aurora kann...
...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora
![Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.
Fourth Quarter 2019 Highlights:
-
Revenue grew 37% versus the
![Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.
Fourth Quarter 2019 Highlights:
-
Revenue grew 37% versus the
![Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’
![Quidel Reports Fourth Quarter and Full Year 2019 Financial Results](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Global